Impact of Cerebral Small Vessel Disease on Functional Decline: Insights from the Bleeding With Antithrombotic Therapy 2 Study and Related Evidence
Highlights
- Cerebral small vessel disease (SVD) burden independently predicts functional decline in patients receiving oral antithrombotic therapy for cerebrovascular or cardiovascular diseases.
- Higher SVD scores (≥3) are associated with significantly increased odds of worsening disability as measured by the modified Rankin Scale (mRS) over 24 months.
- Functional decline attributed to SVD is predominantly a direct effect, not fully mediated by major bleeding or ischemic events during follow-up.
- Early neurological deterioration in lacunar stroke and pre-existing leukoaraiosis are additional clinical facets of SVD, influencing outcomes and therapeutic considerations.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.